Patricia Coyle, MD
Neurology · East Setauket, NYNPI 1124068713
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Sanofi at 32.6% of the total. Reporting peaked in 2019 at $248,823 and has fallen 83.5% since, to $41,057 in 2025. Among neurology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 419 payments — averaging $1636.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$224K
- Sanofi-aventis U.S. LLC$71K
- EMD Serono, Inc.$66K
- Biogen$58K
- Novartis$57K
- Amgen$39K
- plus $172K from 19 others
Across 291 payments — averaging $4447.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$371K
- Novartis$337K
- F. Hoffmann-la Roche AG$228K
- Genentech, Inc.$168K
- Roche Products Limited$79K
- Janssen Research & Development, LLC$50K
- plus $61K from 4 others
What the payments were for
- Consulting fees$353,12452%
- Speaking & faculty fees$212,22131%
- Travel & lodging$81,19012%
- Food & beverage$7,8951%
- Education$31,1195%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 98 | $223,826 |
| Sanofi-aventis U.S. LLC | 21 | $70,640 |
| EMD Serono, Inc. | 52 | $65,899 |
| Biogen | 32 | $57,847 |
| Novartis | 31 | $56,892 |
| Amgen(2 entities) | 35 | $38,714 |
| AstraZeneca | 29 | $31,907 |
| Novartis Pharma AG | 14 | $27,036 |
| GSK | 11 | $24,972 |
| Johnson & Johnson | 29 | $24,621 |
| E.r. Squibb & Sons, L.L.C. | 4 | $18,369 |
| Mylan Institutional Inc. | 6 | $7,055 |
| Hoffmann-la Roche Limited | 3 | $6,862 |
| Eli Lilly | 9 | $6,345 |
| Genentech USA, Inc. | 6 | $5,922 |
| Mylan Specialty L.p. | 6 | $5,603 |
| Bristol Myers Squibb | 11 | $5,006 |
| TG Therapeutics, Inc. | 6 | $3,373 |
| Bayer | 3 | $1,569 |
| Janssen Scientific Affairs, LLC | 1 | $1,320 |
| Janssen Global Services, LLC | 1 | $1,320 |
| BD | 1 | $151 |
| AbbVie(2 entities) | 7 | $149 |
| Davol Inc. | 2 | $129 |
| CSL Behring | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUBAGIO$111,358
- LEMTRADA$55,685
- UPLIZNA$38,218
- NO PRODUCT DISCUSSED$32,271
- MZT_MAYZENT_NEUROSCIENCE$16,980
- Mavenclad$16,256
- KESIMPTA$15,830
- SHINGRIX$14,460
- SOLIRIS$13,174
- ZEPOSIA$12,387
- PLEGRIDY$12,100
- DISEASE STATE$10,925
- BAF312A_MAYZENT_NEUROSCIENCE$9,948
- MAYZENT$8,932
- TECFIDERA$8,451
- Glatiramer Acetate$6,951
- OCREVUS$6,862
- Non-Covered Product$5,915
- ULTOMIRIS$2,840
- Ponvory$2,640
How this compares
$685,548 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OcrevusOcrelizumab | 17 | $665,919 |
| CopaxoneGlatiramer Acetate | 42 | $425,491 |
| TecfideraDimethyl Fumarate | 29 | $317,473 |
| MayzentSiponimod | 12 | $133,821 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 17 | $103,644 |
| BetaseronInterferon Beta-1b | 11 | $103,604 |
| Teriflunomide | 29 | $92,997 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 12 | $89,565 |
| Carbamazepine ErCarbamazepine | 16 | $2,406 |
| Baclofen | 43 | $983 |
| Gabapentin | 31 | $872 |
| Oxybutynin Chloride ErOxybutynin Chloride | 19 | $643 |
| Pregabalin | 17 | $441 |
| Methylprednisolone Sodium SuccMethylprednisolone Sod Succ | 14 | $327 |
| Nortriptyline Hcl | 11 | $270 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenTecfidera | $57,847 | $317,47329 claims |
| NovartisMayzent | $56,892 | $133,82112 claims |
| CSL BehringPrivigen | $20 | $103,64417 claims |
| BayerBetaseron | $1,569 | $103,60411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,623 neurology providers in New York.
Other neurology in East Setauket
- Patricia MelvilleEast Setauket$337K
- Idan SharonBrooklyn$2.1M
- Allan PerelStaten Island$1.7M
- Nicolas SaikaliAmherst$1.5M
- David KreitzmanCommack$1.5M
- Charles ArgoffAlbany$1.2M
- Stephen KriegerNew York$1.1M
- Robert FeketeHawthorne$1M
- Jennifer McVigeAmherst$982K
- Warren SpinnerPort Jefferson Station$791K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.